25
Jun
Jun
As regulatory pressure mounts on synthetic cannabinoids like ADB-BUTINACA, a new wave of analogues is emerging to fill the void—leading the pack is 7-ADD, often referred to as the ADB-BUTINACA replacement. Known within research circles for its structural similarity and potent activity at cannabinoid receptors, 7-ADD is gaining rapid attention as a promising alternative for […]